Group 1: Pharmaceutical Business Direction - The pharmaceutical business group aims to be a model for the inheritance and innovative development of traditional Chinese medicine, focusing on optimizing existing products and providing comprehensive operational plans for major disease treatment areas such as cardiovascular, respiratory, and pediatrics [2] - The group will continue secondary development of existing products and selectively extend external projects to strengthen the pharmaceutical system [2] Group 2: Traditional Chinese Medicine Industry Chain Development - The company is committed to building a world-class modern traditional Chinese medicine industry in Yunnan, focusing on seed industry, planting, processing, marketing, and branding [3] - A specialized company for traditional Chinese medicine seed industry has been established, with 7 GAP varieties applied for in 2024 covering 4,593 acres [4] - The production of Qi Xue Kang oral liquid won the title of Yunnan Province's manufacturing single champion, with a 180% increase in production during the reporting period [4] - The "Shuzhi Yun Yao" platform was launched, achieving over 100 million yuan in transaction volume, enhancing the standardization of traditional agricultural products [4] Group 3: Yao Yuan Qing Product Performance - In 2024, Yao Yuan Qing hair care products achieved sales revenue of 422 million yuan, a year-on-year increase of 30.3% [5] - The brand has gained significant market penetration, ranking first in Tmall's domestic anti-hair loss shampoo category during major sales events [6] Group 4: Q1 2025 Financial Performance - In Q1 2025, the company reported revenue of 10.841 billion yuan, a year-on-year increase of 0.62% [7] - Net profit attributable to shareholders was 1.935 billion yuan, up 13.67% year-on-year, with a basic earnings per share of 1.08 yuan [7] - The net cash flow from operating activities increased by 35.39% to 714 million yuan [7] Group 5: Health Product Channel Development - The company has a well-established national sales team for health products, maintaining a leading market share in toothpaste [8] - Continuous optimization of the entire channel has strengthened traditional offline advantages while exploring new retail formats [9]

Group 1: Future Development Plans - The pharmaceutical business group aims to be a model for the inheritance and innovative development of traditional Chinese medicine, focusing on major disease treatment areas such as cardiovascular, respiratory, and pediatrics [2] - The strategy includes optimizing the existing product system and providing comprehensive operational plans to achieve strategic growth [2] Group 2: Health Products Business Performance - In 2024, the health products business achieved revenue of CNY 6.526 billion, a year-on-year increase of 1.6%, and profit of CNY 2.191 billion, up 8.36% [3] - The oral care segment maintained the top market share in China, while the anti-hair loss product line saw a revenue increase of 30.3% [4] Group 3: Traditional Chinese Medicine Supply Chain Development - The company is committed to developing Yunnan's traditional Chinese medicine industry, establishing a specialized seed company and applying for GAP certification for 7 varieties covering 4,593 acres [5] - The production of medicinal materials increased significantly, with a 180% rise in output and a 182% increase in food and health product production [6] Group 4: Dividend Distribution - The company plans to distribute a cash dividend of CNY 11.85 per 10 shares, with a total cash dividend amounting to CNY 4.278 billion, representing 90.09% of the net profit attributable to shareholders for 2024 [7]